Aligos Therapeuticsinc Stock Filter Stocks by Fundamentals
ALGS Stock | USD 0.98 0.04 3.92% |
Aligos TherapeuticsInc fundamentals help investors to digest information that contributes to Aligos TherapeuticsInc's financial success or failures. It also enables traders to predict the movement of Aligos Stock. The fundamental analysis module provides a way to measure Aligos TherapeuticsInc's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aligos TherapeuticsInc stock.
Aligos | Shares Owned by Institutions |
Aligos TherapeuticsInc Institutional Holders
Institutional Holdings refers to the ownership stake in Aligos TherapeuticsInc that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Aligos TherapeuticsInc's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Aligos TherapeuticsInc's value.Shares | Bank Of America Corp | 2023-12-31 | 1.1 M | Vanguard Group Inc | 2023-12-31 | 1 M | Pivotal Bioventure Partners Investment Advisor Llc | 2023-12-31 | 743.2 K | Silverarc Capital Management, Llc | 2023-12-31 | 668.5 K | Acadian Asset Management Llc | 2023-12-31 | 559.4 K | Renaissance Technologies Corp | 2023-12-31 | 490 K | Geode Capital Management, Llc | 2023-12-31 | 321 K | Blackrock Inc | 2023-12-31 | 296.1 K | State Street Corporation | 2023-12-31 | 97.4 K | Armistice Capital, Llc | 2023-12-31 | 6.8 M | Ecor1 Capital, Llc | 2023-12-31 | 6.4 M |
Aligos Fundamentals
Return On Equity | -0.89 | ||||
Return On Asset | -0.37 | ||||
Operating Margin | (9.43) % | ||||
Current Valuation | (47.38 M) | ||||
Shares Outstanding | 72.58 M | ||||
Shares Owned By Insiders | 21.07 % | ||||
Shares Owned By Institutions | 62.00 % | ||||
Number Of Shares Shorted | 365.6 K | ||||
Price To Book | 0.84 X | ||||
Price To Sales | 4.87 X | ||||
Revenue | 15.53 M | ||||
Gross Profit | (71.17 M) | ||||
EBITDA | (84.36 M) | ||||
Net Income | (87.68 M) | ||||
Cash And Equivalents | 159.34 M | ||||
Cash Per Share | 3.72 X | ||||
Total Debt | 11.14 M | ||||
Debt To Equity | 0.1 % | ||||
Current Ratio | 5.30 X | ||||
Book Value Per Share | 1.23 X | ||||
Cash Flow From Operations | (79 M) | ||||
Short Ratio | 0.97 X | ||||
Earnings Per Share | (1.36) X | ||||
Target Price | 4.0 | ||||
Number Of Employees | 66 | ||||
Beta | 2.34 | ||||
Market Capitalization | 75.67 M | ||||
Total Asset | 153.9 M | ||||
Retained Earnings | (486.8 M) | ||||
Working Capital | 117.18 M | ||||
Z Score | -1.15 | ||||
Net Asset | 153.9 M |
About Aligos TherapeuticsInc Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aligos TherapeuticsInc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aligos TherapeuticsInc using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aligos TherapeuticsInc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. The company was incorporated in 2018 and is headquartered in South San Francisco, California. Aligos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people.
Pair Trading with Aligos TherapeuticsInc
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aligos TherapeuticsInc position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aligos TherapeuticsInc will appreciate offsetting losses from the drop in the long position's value.Moving together with Aligos Stock
0.68 | MDGL | Madrigal Pharmaceuticals Financial Report 14th of May 2024 | PairCorr |
0.68 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
Moving against Aligos Stock
0.92 | TFX | Teleflex Incorporated Financial Report 2nd of May 2024 | PairCorr |
0.82 | KA | Kineta Inc Report 29th of March 2024 | PairCorr |
0.6 | MEIP | MEI Pharma Financial Report 9th of May 2024 | PairCorr |
0.57 | VBIV | VBI Vaccines Financial Report 20th of May 2024 | PairCorr |
0.57 | DBVT | DBV Technologies Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Aligos TherapeuticsInc could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aligos TherapeuticsInc when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aligos TherapeuticsInc - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aligos TherapeuticsInc to buy it.
The correlation of Aligos TherapeuticsInc is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aligos TherapeuticsInc moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aligos TherapeuticsInc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aligos TherapeuticsInc can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Aligos TherapeuticsInc Piotroski F Score and Aligos TherapeuticsInc Altman Z Score analysis. For more information on how to buy Aligos Stock please use our How to Invest in Aligos TherapeuticsInc guide.Note that the Aligos TherapeuticsInc information on this page should be used as a complementary analysis to other Aligos TherapeuticsInc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for Aligos Stock analysis
When running Aligos TherapeuticsInc's price analysis, check to measure Aligos TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos TherapeuticsInc is operating at the current time. Most of Aligos TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of Aligos TherapeuticsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos TherapeuticsInc's price. Additionally, you may evaluate how the addition of Aligos TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is Aligos TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aligos TherapeuticsInc. If investors know Aligos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aligos TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.36) | Revenue Per Share 0.242 | Quarterly Revenue Growth (0.24) | Return On Assets (0.37) | Return On Equity (0.89) |
The market value of Aligos TherapeuticsInc is measured differently than its book value, which is the value of Aligos that is recorded on the company's balance sheet. Investors also form their own opinion of Aligos TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is Aligos TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aligos TherapeuticsInc's market value can be influenced by many factors that don't directly affect Aligos TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aligos TherapeuticsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Aligos TherapeuticsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aligos TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.